In Vitro and In Vivo Activity of Peptidomimetic Compounds That Target the Periodontal Pathogen Porphyromonas gingivalis

Antimicrobial Agents and Chemotherapy
Jinlian TanDonald R Demuth

Abstract

The interaction of the periodontal pathogen Porphyromonas gingivalis with oral streptococci is important for initial colonization of the oral cavity by P. gingivalis and is mediated by a discrete motif of the streptococcal antigen I/II protein. A synthetic peptide encompassing this motif functions as a potent inhibitor of P. gingivalis adherence, but the use of peptides as topically applied therapeutic agents in the oral cavity has limitations arising from the relatively high cost of peptide synthesis and their susceptibility to degradation by proteases expressed by oral organisms. In this study, we demonstrate the in vitro and in vivo activity of five small-molecule mimetic compounds of the streptococcal peptide. Using a three-species biofilm model, all five compounds were shown to effectively inhibit the incorporation of P. gingivalis into in vitro biofilms and exhibited 50% inhibitory concentrations (IC50s) of 10 to 20 μM. Four of the five compounds also significantly reduced maxillary alveolar bone resorption induced by P. gingivalis infection in a mouse model of periodontitis. All of the compounds were nontoxic toward a human telomerase immortalized gingival keratinocyte cell line. Three compounds exhibited slight toxicity...Continue Reading

References

Mar 12, 1998·Journal of Clinical Periodontology·S S SocranskyR L Kent
Jul 10, 2002·Periodontology 2000·Aubrey Sheiham, Gopalakrishnan S Netuveli
Jul 10, 2002·Periodontology 2000·Esmonde F CorbetEdward C M Lo
Dec 30, 2003·Journal of Medicinal Chemistry·John W Clader
Dec 16, 2004·Angewandte Chemie·Vani P MocharlaHartmuth C Kolb
Jun 24, 2005·Infection and Immunity·Yoonsuk ParkRichard J Lamont
Sep 22, 2006·Infection and Immunity·Carlo Amorin DaepDonald R Demuth
Sep 26, 2006·Odontology·Jemin Kim, Salomon Amar
Dec 3, 2011·Periodontology 2000·Bruce A Dye
Sep 4, 2012·Nature Reviews. Microbiology·George HajishengallisMichael A Curtis
Dec 21, 2012·Molecular Oral Microbiology·C J WrightH F Jenkinson
Apr 12, 2013·Periodontology 2000·Robert J Genco, Wenche S Borgnakke
Dec 17, 2014·Trends in Molecular Medicine·Richard J Lamont, George Hajishengallis
Feb 18, 2015·Journal of Periodontology·Paul I EkeRobert J Genco
Oct 17, 2012·Tetrahedron Letters·Catherine M LonerDonald R Demuth
Jun 30, 2015·Tetrahedron Letters·Pravin C PatilDonald R Demuth
Jul 23, 2015·Journal of Medicinal Chemistry·Eric P GillisNicholas A Meanwell
Aug 9, 2016·Molecular Oral Microbiology·C LiuR J Lamont
Sep 21, 2016·Bioorganic & Medicinal Chemistry·Pravin C PatilFrederick A Luzzio
Mar 16, 2017·Frontiers in Microbiology·Erik L HendricksonMurray Hackett
Feb 6, 2018·Journal of Medicinal Chemistry·Nicholas A Meanwell

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
confocal microscopy

Software Mentioned

GraphPad InStat3
Volocity
GraphPad Instat

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.